New revolving credit facility of CHF 250 million for Swiss Medical Network SA

Aevis Victoria

AEVIS VICTORIA SA / Key word(s): Miscellaneous

06-May-2022 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 6 May 2022

AEVIS VICTORIA SA: New revolving credit facility of CHF 250 million for Swiss Medical Network SA

Swiss Medical Network SA, the second largest private hospital and clinic group in Switzerland and the largest subsidiary of AEVIS VICTORIA SA, signed a new CHF 250 million revolving credit facility provided by a Swiss banking syndicate led by Credit Suisse (Schweiz) AG. This credit facility replaces the existing CHF 120 million revolving credit line implemented in 2017.

The five-year credit facility is made available to the hospital network for general business purposes and future acquisitions. Thanks to the improved maturity level of Swiss Medical Network, the new revolving credit facility provides more advantageous terms and covenants as well as increased flexibility to the group.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing ten luxury hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

 

Additional features:

File: AEVIS VICTORIA SA: New revolving credit facility of CHF 250 million for Swiss Medical Network SA


End of ad hoc announcement

Categories: News

Tags:

Navamedic acquires Impolin AB and broadens obesity portfolio

Reiten

Navamedic announced on Thursday 5th of May that it has entered into a share purchase agreement with Agnvicen AB to acquire 100% of the shares in Impolin AB for a purchase price of SEK 50 mill on a debt and cash free basis. The acquisition strengthens Navamedic’s position in the market for obesity treatment, enabling them to support patients and consumers during weight loss or obesity treatment.

Impolin AB is a Stockholm based company that specializes in products related to the pre- and post-treatment for bariatric surgery. Impolin’s portfolio includes Modifast, a range of diet and meal replacement products, and MedMade, a multivitamin and minerals tablet for post-bariatric surgery supplementation, which are products aimed at supporting patients during weight loss or obesity treatment, including bariatric surgery. Navamedic’s addition of Modifast and MedMade is set to broaden their current product offering within the area of obesity treatment, which enables the company to support patients throughout the entire weight loss journey.

“Our ambitions are bold, but by capitalizing on the strong transaction synergies, I am confident that we will successfully launch our expanded product range across the Nordic territory. Together with the Impolin team, we are planning to launch Modifast in Norway in 2023, followed by rollout in Finland and Denmark, and double product revenue by the end of 2028,” commented Kathrine Gamborg Andreassen, CEO of Navamedic.

“Navamedic has dedicated part of its product portfolio to treating obesity, making the company our preferred partner. With Navamedic’s position as a reliable supplier of high-quality products in the Nordics, we believe this agreement will accelerate access to our products for patients outside of Sweden. I look forward to collaborating closely with the team at Navamedic to contribute to improving the quality of life for people,” said Tony Brejke, Managing Director and owner of Impolin AB.

Navamedic will settle SEK 25 mill of the purchase price by way of issuing new shares to the seller through conversion of an account receivable to be issued by Navamedic to the seller at closing. The remaining portion of the purchase price will be settled in cash. In addition, the seller may be entitled to an additional consideration in the amount of SEK 5 mill if certain pre-agreed milestones for Impolin AB are satisfied by year-end 2022. The subscription price for the new shares shall be equal to the volume weighted average share price of the Company’s shares on the Oslo Stock Exchange during the period from 31 December 2021 to the closing date of the transaction. The consideration shares will be listed on the Oslo Stock Exchange and be subject to a lock-up period of 24 months from the closing date. The board of directors of Navamedic will issue the consideration shares pursuant to an authorization to issue new shares granted to it by the general meeting of the Company on 3 June 2021 or, if completion occurs after the expiry of such authorization, a new authorization to be approved by the Annual General Meeting of the Company.

The completion of the transaction is subject to Impolin AB amending one of its material agreements on terms and conditions satisfactory to Navamedic, in addition to certain customary conditions. It is expected that the transaction will be completed during Q2 2022.

Go to press release

Categories: News

Tags:

American Laboratory Products Company Merges with GeneProof

Ampersand

American Laboratory Products Company Merges with GeneProof

SALEM, N.H. and BRNO, Czech Republic, April 21, 2022 /PRNewswire/ — American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader in the diagnostic products market, with broad capabilities spanning novel immunoassay testing kits, real-time PCR testing products, and automated laboratory instrumentation solutions.

GeneProof was founded over 15 years ago by Drs. Radek Horvath and Milos Dendis and is an established market leader in the molecular diagnostics field. Both Founders will remain with the merged company and continue as significant shareholders. GeneProof is the largest producer of PCR reagents in the Czech Republic and distributes its portfolio of more than 70 CE-marked molecular diagnostic tests and instruments throughout Europe, Africa, the Middle East, and South America. Products are primarily focused on the infectious and genetic diseases. With a strong emphasis on quality, GeneProof offers technologically advanced real-time PCR kits and user-friendly automated instrument platforms for both nucleic acid extraction and sample-to-answer testing that meet the diverse throughput needs of laboratories.

The combined company is majority owned by Ampersand Capital Partners (“Ampersand”), which first invested in ALPCO in 2020.

“ALPCO and GeneProof have both earned great reputations in their respective markets, ALPCO in immunodiagnostics and GeneProof in molecular diagnostics,” said Sean Conley, President and CEO of ALPCO. “The combination of the two companies transforms both organizations into a more complete solutions provider and aligns well with ALPCO’s strategy of investing in proprietary automated platforms.”

Radek Horvath, CEO of GeneProof, added, “This strategic connection represents a new chapter in the life of both companies. It will facilitate the entry of GeneProof products into the US market, and similarly, expand the presence of ALPCO products into the EU and around the world. The combination of deep knowledge in the field of molecular diagnostics as well as in the field of immunological diagnostics will bring a significant synergistic effect. The two merged companies intend to use each other’s technological experience and rely on the support of our strong partner, Ampersand, for further development.”

Eric Lev, General Partner at Ampersand and Board member of ALPCO added, “I look forward to working with Sean, Radek, and Milos as we build the combined company into a fully integrated global leader in the field of diagnostics and commercialize GeneProof’s fully automated real-time PCR offerings in the North American market.”



About ALPCO

American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since evolved into a leading producer of novel immunodiagnostic reagents for specialty testing laboratories. In September of 2020, ALPCO announced the recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment was sought to accelerate ALPCO’s global growth initiatives, including the expansion of the company’s diagnostics reagent offering, broadening the company’s geographic presence, and fueling technological advancement. For additional information, please visit www.alpco.com.

About GeneProof

Based in Brno, Czech Republic, GeneProof a.s. was founded in 2005 by Dr. Radek Horvath and Dr. Milos Dendis. GeneProof offers a wide range of in vitro molecular diagnostic products, primarily focused on the infectious diseases and genetic mutations. The Company has established a portfolio of more than 70 CE-marked PCR test kits and a proprietary instrumentation offering to serve laboratories of all sizes. GeneProof’s sales and distribution network covers more than 60 countries around the world. For detailed information see www.geneproof.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com.

Categories: News

Tags:

GBL acquires a majority stake in Sanoptis, a European leader in ophthalmology clinics, to accelerate the company’s growth in partnership with its management and doctors

GBL

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in Sanoptis,
a leading network of ophthalmology clinics across Germany and Switzerland, from Telemos Capital (“Telemos”). GBL
is committing up to EUR 750 million in equity for this transaction. As part of the transaction, the incumbent
management will increase its stake in the company by way of a substantial reinvestment. GBL and management plan
to continue together the impressive growth story of Sanoptis, both in existing markets as well as in new, attractive
European geographies.

Founded in 2018, Sanoptis has rapidly grown to become the second largest European ophthalmology services provider
with over 250 facilities, serving both publicly and privately insured patients. For GBL and management, the ambition
will be to continue Sanoptis’ growth organically and through acquisitions. The company will remain focused on
adhering to the highest quality standards while delivering essential medical services of the highest grade to the
German and Swiss population in partnership with local regulators and payors. Further growth will increase the depth
and breadth of these high-quality services.
Sanoptis has a unique business model; it targets active partnerships with leading surgeons who remain shareholders
in their clinics after joining the Sanoptis group. Within its network, Sanoptis drives growth by: (i) sharing medical and
other best practices while preserving the doctors’ autonomy and (ii) implementing cutting-edge medical innovations
while investing in top-notch equipment. GBL strongly believes in this partnership model and envisions to further
grow Sanoptis along the same strategy.

This transaction marks GBL’s second consecutive private investment in the healthcare sector in 2022. Healthcare is one
of GBL’s four focus investment sectors, along with consumer experience, technology and sustainability. The Sanoptis
transaction also corresponds to GBL’s ambition to increase the representation of controlled private and alternative
assets within its portfolio. The group’s long-term objective is that private and alternative investments account for
approximately 40% of its portfolio (versus 25% as of end 2021).
Ian Gallienne, CEO of GBL, commented: “As a private asset in the highly-attractive healthcare sector, Sanoptis is an excellent
fit with our investment strategy. Together with management, we look forward to further solidifying Sanoptis’ leadership positions
in its core markets as well as expanding into other European countries.”
Michal Chalaczkiewicz, GBL Investment Partner, added: “Sanoptis is at the forefront of the ophthalmology field, which is
supported by long-term, resilient growth, underpinned by secular trends. We believe Sanoptis’ unique partnership model with
doctors is its most important asset, which will support the continuation of its impressive growth trajectory.”
Jens Riedl, GBL Investment Partner responsible for the DACH region, stated: “After our acquisition of Canyon,
the fast-growing direct-to-consumer manufacturer and seller of premium bicycles, Sanoptis is our second private investment in
DACH, where we have the opportunity to team up with an exceptional team of entrepreneurs.”
For Volker Wendel, Founder and CEO of Sanoptis: “We are excited to continue our success story with a strong and
sustainable partner who fully supports our doctor-oriented culture and entrepreneurial strategy. Continuing business in the same
way as we did in the last four years, we see a lot of potential for future growth in DACH and other European countries. That’s
why management remains fully committed and will substantially increase its stake in the company.”
GBL has been advised by Goldman Sachs, Bain & Company, EY and Kirkland & Ellis.

Delivering meaningful growth
Privileged and regulated information – April 20, 2022 // Page 2 / 2 // For more information: www.gbl.be
The transaction is expected to be completed in the second quarter of 2022.
For more information, please contact:
Xavier Likin Alison Donohoe
Chief Financial Officer Head of Investor Relations
Tel: +32 2 289 17 72 Tel: +32 2 289 17 64
xlikin@gbl.be adonohoe@gbl.be

About Sanoptis
Sanoptis is a leading German and Swiss ophthalmology services provider with approximately EUR 300 million of
revenue in 2021. Founded in 2018 by CEO Volker Wendel and CDO Carsten Horn, Sanoptis has rapidly grown to
become a leading European ophthalmology services provider, with over 250 facilities across Germany and
Switzerland, serving both publicly and privately insured patients. The company offers both conservative
ophthalmology consultations and surgical treatments including cataract surgeries, intravitreal operative medicine
injections (IVOM), laser eye surgeries and retina surgeries. Sanoptis performs over 1.3 million consultations and
170,000 surgical procedures annually, while adhering to the highest standards of healthcare through its leading
doctor base and thorough quality management.

About Telemos Capital
Telemos comprises a team of highly experienced investment professionals that combine the best of private equity
and permanent capital. Founded in 2017, Telemos identifies and supports exceptional management teams in
consumer goods, healthcare services, and business services to help them realise their long-term objectives. As a
flexible and nimble investor, Telemos’ distinct structure and expertise make it a leading, new generation European
private equity firm, looking to identify and unlock attractive opportunities for growth and value creation.

About Groupe Bruxelles Lambert
Groupe Bruxelles Lambert (“GBL”) is an established investment holding company, with over sixty years of stock
exchange listing, a net asset value of EUR 22.5 billion and a market capitalization of EUR 15.3 billion at the end of
December 2021. GBL is a leading investor in Europe, focused on long-term value creation and relying on a stable and
supportive family shareholder base. GBL is both a responsible company and investor and perceives ESG factors as
being inextricably linked to value creation.
GBL strives to maintain a diversified high-quality portfolio of listed and private assets as well as alternative
investments (through Sienna Investment Managers, the group’s alternative investment platform), composed of
international companies that are leaders in their sectors, to which it can contribute to value creation by being an
active, supportive and professional investor.
GBL is focused on delivering meaningful growth by providing attractive returns to its shareholders through a
combination of growth in its net asset value, a sustainable dividend and share buybacks.
GBL is listed on the Euronext Brussels stock exchange (Ticker: GBLB BB; ISIN code: BE0003797140) and is included
in the BEL20 index

Categories: News

Tags:

Reema Health Secures $8 Million in Seed Funding Round

New Stack Ventures

Investments in breakthrough community-based health technology platform top $10 million to date.

April 11, 2022 · Portfolio Company

Reema Health, a community-based health technology platform, recently earned $8 million in a funding round led by MaC Venture Capital and DNA Capital. Combined with a previous $1.25 million pre-seed round and earlier preliminary investments, Reema’s has raised over $10 million to date.

58% of low-income Americans report being socially isolated, a factor that impacts their overall health and significantly increases the cost of care. Reema transforms how people navigate the gaps between health care and social care by combining advanced technology with human interaction. Reema’s personalized, community-based approach engages people via Community Guides with a personal understanding of their lives, their crucial needs, and the most impactful resources available. Reema’s technology platform empowers Guides to be more effective, helping them rapidly establish the kind of deep trust proven to promote better health outcomes.

“Technology solutions can create more efficient, and more informed outreach but they can’t build authentic relationships that drive real engagement,” said Justin Ley, CEO of Reema.

“Our experienced Community Guides work one-on-one with the most underserved people in their communities when it comes to social care. It’s the latest data science combined with empathic, in-person relationships, a powerful combination that builds trust fast.” Ley added the inspiration for Reema came from his own personal experiences growing up.

Reema is currently serving health plans throughout the East Coast and Midwest, with plans to expand to several more states this year. The company’s current programs are already reporting member engagement rates of 84% or more, a metric that proves its breakthrough approach is successfully reaching many people who, before Reema, were living without the social care that significantly improves their lives, and the overall health of their communities.

“Health plans, providers and other intermediaries have realized that piling on more and more clinical and social resources barely moves the needle when it comes to driving desirable health outcomes for marginalized, low income population,” said Partha Mishra, Partner at DNA Capital. “Acting as a catalyst, combining technology and human insights, and partnering with existing players, Reema has instead demonstrated that a personalized, community centric approach to build bridges with each member first makes the entire system come alive.”

About Reema:

Reema uses technology to power human relationships with the goal of improving health outcomes for people who are hardest to reach. Reema’s breakthrough health platform uses proprietary technology and predictive data modeling to identify people with the highest level of unmet social needs, and power Community Guides with the right information to engage them meaningfully, connect them with the most relevant resources, and improve their health and their lives. For more information visit ReemaHealth.com.

 

Categories: News

Tags:

CVC Fund VI agrees exit of Theramex

CVC Capital Partners

28 Mar 2022

Global investment firms PAI Partners and Carlyle (NASDAQ: CG) today announce that they have agreed to acquire Theramex, the leading global specialty pharmaceuticals company focused on women’s health, from CVC Capital Partners VI (“CVC”).

Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018, and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health. The company provides patient-focused solutions across contraception, fertility, menopause, and osteoporosis with the aim of providing patients with products that can support them through their life journey. Under CVC Funds’ ownership, Theramex has focussed on building loyal relationships with physicians through its dedicated sales force, investing in digital capabilities and executing a successful M&A agenda to bring new products to market in the future, resulting in double digit revenue and EBITDA growth since 2018.  The company now serves more than six million women in 57 countries across EMEA, APAC and South America, and employs approximately 480 people (~60% of whom are women).

With the support of Carlyle and PAI Partners, Theramex will seek to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion. The investment in Theramex builds on Carlyle’s long-term global focus on Healthcare, a sector in which the firm has invested $15 billion to date. Carlyle has significant expertise in scaling global Pharma businesses, such as iNova, Curia and PPD, and specifically in women’s health, through its investment in Millicent Pharma. Similarly, PAI will utilise its deep sector experience in healthcare to support Theramex’s growth trajectory. Healthcare is one of PAI’s four core sectors of focus, in which the firm has made ten investments, including in pharmaceutical companies, Ethypharm and Ipsen.

Robert Stewart, CEO of Theramex said: “I am delighted to have the support of both Carlyle and PAI Partners investing in the business, which will allow us to further accelerate our growth. I also want to thank CVC for being such a fantastic partner over the last years. Together, we have built one of the world’s largest pharmaceutical companies dedicated solely to women’s health, improving lives and ensuring these important products are made available to all who need them.”

Sebastien Veil and Andreas Kumeth, both Partners at PAI, said: “We were attracted to Theramex given its strong heritage in women’s health and outstanding reputation for delivering effective and safe solutions that support and care for women around the world. We look forward to leveraging PAI’s extensive healthcare network and capital to support organic and inorganic growth initiatives for Theramex and partnering with the management team to support the continued expansion of the platform.”

Lubna Qunash and Philipp Meyer, both Managing Directors of the Carlyle Europe Partners advisory team, said: “We believe that Theramex’s long-standing and established position as a women’s health champion with a broad and complementary product portfolio are distinctive attributes which position the business well for continued success. This acquisition demonstrates our strategic commitment to the Healthcare sector in Europe, and together with PAI, we look forward to partnering with the Theramex management team and utilising our significant resources and global network to support their international growth ambitions.”

Cathrin Petty, a Managing Partner and Global Head of Healthcare at CVC, said: “Theramex has been at the forefront of raising awareness and delivering better therapies for women across the globe, particularly in relation to menopause, endometriosis and osteoporosis. As a team, we are very proud to have supported the fantastic Theramex leadership, from the head office through supply chain experts, through to the country leadership and our dedicated sales force – all of whom have a dedication to making a difference to women’s lives. We wish the team every success in the next chapter of growth.”

Carlyle and PAI Partners were jointly advised by Morgan Stanley, Jefferies and Greenhill & Co (M&A), and Linklaters and Allen & Overy (Legal), and PwC (Financial). CVC was advised by Rothschild & Co, HSBC (M&A) and Latham & Watkins (Legal), and EY (Financial), and IQVIA (Commercial).

The financial terms of the transaction are not being disclosed.

Categories: News

Tags:

Corus and Signadens join forces for European leadership in digital dentures

Quadrum Capital

Barcelona (ES)/Amersfoort (NL), 23rd of March 2022 – Dutch-Belgian Signadens has joined forces with Corus, the leading dental laboratory group in Spain, France and Portugal. Under the name Corus, they aim to consolidate their position at the forefront of technology and innovation and become market leaders in the field of European digital dental prostheses. The integration creates a cluster with 49 laboratories and 1,200 employees, supporting 9,000 dental practices in five countries in the ongoing modernisation and digital transformation of the industry.

image

The co-directors of the new Corus, Nicolas Bonnard, Jeroen Van Asten and Juan Roma.

As part of its strategy, Corus aims to integrate local entrepreneurs who then become shareholders of the company, while maintaining the highest level of service locally for their existing customers. Corus operates as an integrated digital platform where dentists can communicate with the local laboratory and patient, while at the same time ensuring prescription traceability and the information needed to tailor products and services to the patient. Together with the integration of the wider network of laboratories, this provides a global solution based on an innovative and differentiated portfolio of working protocols, products, services and training and education while maintaining a local and personalised approach, ensuring better dental care and patient experience.

Corus and Signadens will reach a consolidated turnover of €100 million by the end of 2021. Following the integration, the company plans to grow the business further through a combination of organic growth and the consolidation of more laboratories, both in the current regions and beyond. Current private equity investors Careventures and Quadrum Capital have pledged their support for the company’s future growth plans.

Corus is led by co-CEOs Jeroen van Asten (Signadens) and Nicolas Bonnard (Corus). They will share responsibilities for the development of the company, with Van Asten as CEO for the Netherlands and Belgium. Van Asten: “The European market for dental prostheses is undergoing a consolidation process. Digitisation is bringing about far-reaching changes. In the coming years, we want to play a leading role in this transformation by integrating leading laboratories and leveraging the group’s capacity for innovation. We look forward to further expanding our products and services in the European market. Countries such as Germany, the UK or Italy have enormous potential, which we are keen to capitalise on.”

Nicolas Bonnard, CEO of Corus Spain, Portugal and France, speaks of a new era: “It is a great honour to take on the challenge of leading and developing our company with very talented entrepreneurial partners and an excellent team of experienced managers. Corus, in cooperation with dentists, is driving the paradigm shift in the new era of dentistry: digital, personalised and with high added value for the dentist and for the patient. Based on our corporate structure, where all laboratories own shares in the group, we are well positioned to provide excellent services and products to our customers in the most efficient way.”

Juan Roma, partner at Careventures and executive chairman of Corus, said, “At Corus, we are committed to the European development of the company. The confidence, talent and results we have achieved in recent years are testament to the success of our work. Joining forces with Signadens greatly strengthens our position as a leader in the market. Moreover, with the leadership of both Nicolas and Jeroen, I have no doubt that we will continue to achieve success as we see Corus grow further into new markets.”

Advisors involved in the transaction were BakerMckenzie, Houthoff, Broseta and Atlas and for the financial DD support Deloitte.

About Corus Corus is the leading European company in the field of advanced dental prosthetics and orthodontics with headquarters in Barcelona. Founded in 2015, Corus is part of the paradigm shift towards a new form of dentistry, 100% digitised, personalised and with added value for the patient. Since its foundation, Corus has integrated 35 dental laboratories, distributed across Spain, France and Portugal, with a team of more than 920 professionals. The European private equity fund Careventures is the main shareholder and investor of Corus, together with the Managing Partners of the group’s laboratory.

About Signadens Signadens was founded in 2016 as a collaborative initiative of independent dental technicians to establish a quality label in dental care, “Certified by Signadens”, by: (i) investing in automation and digitalisation of activities; (ii) unburdening dental technicians by centralising non-dental activities; (iii) pooling purchasing volume and jointly achieving economies of scale. In December 2020, Dutch mid-market private equity party Quadrum Capital acquired approximately 60% of the company to implement a build-and-buy strategy to consolidate the dental laboratory market in the Benelux and Germany.

About Careventures Careventures is a pan-European private equity firm based in Brussels and Barcelona, specializing in projects for healthcare services.

Categories: News

Tags:

Audax Private Equity Announces Agreement to Sell Lifemark Health Group to Loblaw Companies Limited

Audax Group

Audax Private Equity (“Audax”) today announced that it has entered into a definitive agreement to sell Lifemark Health Group (“Lifemark” or the “Company”), a leading provider of physiotherapy, rehabilitation, and medical assessments in Canada, to Loblaw Companies Limited (TSX: L) (“Loblaw”).

Headquartered in Toronto, ON, Lifemark is a leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. With over 20 years of service, Lifemark is one of the largest and most trusted providers in Canada. As a national healthcare company, Lifemark employs over 5,000 highly trained clinicians, medical experts, and team members in over 300 locations across Canada.

Since partnering with Audax in December 2015, Lifemark has completed over 50 acquisitions, broadened its service offering, and significantly expanded its national footprint. In partnership with Audax, Lifemark also invested heavily in the organic growth of its platform, systems, and key talent to support and sustain continued success.

“Peter and the Lifemark team created a phenomenal business built on the foundation of excellent clinical service,” said Keith Palumbo, Managing Director at Audax Private Equity. “The outpatient physical therapy industry remains highly fragmented and vast, and we’re very proud of the growth we were able to achieve at Lifemark through facility utilization gains, geographic expansion, new services, and acquisitions. We wish them all the best as they continue their journey with Loblaw.”

“At Lifemark, we continually look for the most impactful ways to support Canadians on their healthcare journey, and we are grateful to our partners at Audax for helping us to invest in and develop opportunities that advance physiotherapy and rehabilitation services in Canada,” said Peter Stymiest, Chief Executive Officer of Lifemark Health Group. “We look forward to what the future holds for our patients, clients, and team in partnership with Loblaw.”

The sale of Lifemark is subject to regulatory approvals and other customary closing conditions. The transaction is expected to close in the second quarter of 2022.

Harris Williams is serving as financial advisor and Blake, Cassels & Graydon LLP and Kirkland & Ellis LLP are acting as legal advisors to Audax Private Equity.

Categories: News

Tags:

AEVIS VICTORIA SA sells its participation in Medgate to Otto Group

Aevis Victoria

AEVIS VICTORIA SA / Key word(s): Disposal

10-March-2022 / 17:45 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 10 March 2022

AEVIS VICTORIA SA sells its participation in Medgate to Otto Group

In 2016, the investment company AEVIS VICTORIA SA (AEVIS) acquired a 40% minority stake in Medgate Group, which has now become the leading telemedicine provider in Switzerland with over 20 years of experience. AEVIS has accompanied and financially supported the development of Medgate for 6 years, allowing the creation of a key player in the telemedicine sector in Europe. In the context of a financing round initiated by Medgate in 2021 to finance various acquisitions, amongst others in Germany, AEVIS has sold its participation to the German Otto Group, which will take over this role and accompany Medgate for its further expansion. The proceeds of the sale will significantly strengthen AEVIS’s financial capacity and will be redeployed in its investment activities. The parties have agreed not to disclose the details of the transaction.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing ten luxury hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

 

Additional features:

File: AEVIS VICTORIA SA sells its participation in Medgate to Otto Group


End of ad hoc announcement

Categories: News

Tags:

Better quality of care in outpatient rehabilitation: Gimv portfolio company rehaneo acquires Reha Vita

Topic: Investment

The Munich-based rehaneo Group, one of Germany’s leading providers of outpatient rehabilitation, is integrating Reha Vita in Cottbus, Brandenburg’s largest outpatient rehabilitation centre. In doing so, rehaneo is continuing its consistent growth trajectory and doing everything that it can to ensure that more people can access professional rehabilitation measures close to where they live. Since its foundation mid-2020, the company has been supported by the investment firm Gimv, which recognizes the increasing importance of top-quality outpatient service provision for rehabilitation and has helped to shape the strategy from the very beginning.

rehaneo (www.rehaneo.de) is a rapidly growing provider of outpatient rehabilitation, aftercare, prevention and occupational health management in Germany. Around 18 months ago, Gimv and rehaneo’s managing partner Bruno Crone launched the company as a buy-and-build project with the goal of developing a leading network offering patients access to top-quality, local outpatient care. In doing so, rehaneo is addressing a fragmented growth market as more and more patients want to live at home during their rehabilitation. This improves patients’ quality of life, while the costs of outpatient rehabilitation are also around 40% lower than for inpatient care – for the same quality or even better quality – thereby reducing the burden on the payers.

“rehaneo offers rehabilitation centres a strong partner and an orderly succession opportunity. In addition to our professional competence, we are also placing an emphasis on appreciation and clear values. It is for example important to us to maintain and strengthen the unique character of our rehabilitation centres”, explains Crone. Based on this philosophy, rehaneo was able to win the rehabilitation centre Hunsrück and insa health management still in the founding year 2020. In 2021, the group was able to add rehabilitation centres in Koblenz, Bonn and Göttingen. The recently completed sixth acquisition Reha Vita in Cottbus, has developed from a small physiotherapy practice into a rehabilitation centre with more than 140 employees. In total, the rehaneo group today has more than 600 employees that care for a total of around 30,000 patients and customers a year and support them on their path to a rapid recovery.

Group strategy bears fruit

“From the very beginning, we were enthusiastic about the vision of establishing a leading quality provider in outpatient rehabilitation and we are proud of what has been achieved in such a short period of time”, notes Philipp v. Hammerstein, Partner and the manager responsible for Gimv’s health & care activities in Europe’s German-speaking regions. “We are delighted to be able to actively support rehaneo’s management team with our expertise as an investor specializing in healthcare”, adds Lars Timmer, Principal at Gimv. rehaneo’s strong positioning will be further expanded through additional acquisitions as well as the targeted development of existing rehabilitation centres and the establishment of new ones. The trusting collaboration between Gimv and the management team is a decisive component here. “From day one, we were convinced that Gimv is perfectly suited to us. It has proven to be an agile, hands-on partner with an unparalleled knowledge of the market”, confirms Crone.

Already today, rehaneo sets itself apart through excellent scores in terms of quality and patient satisfaction, advanced digitization with an innovative patient app, a clear commitment to ESG criteria and, not least, a high level of employee satisfaction. “We specifically search for successful, well-established outpatient rehabilitation centres and remedy providers that share our values and recognise the advantages of working together as a larger group”, explains Bruno Crone. “Whether in negotiations with suppliers, through group-wide economies of scale and synergy effects or in terms of further training and education, a group can achieve much more than a standalone centre.”

Categories: News

Tags: